Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Finally, cotreatment with LBH589 and 17-AAG also induced more apoptosis of IM-resistant primary CML-BC and acute myeloid leukemia (AML) cells (with activating mutation of FLT-3) than treatment with either agent alone. 15514006 2005
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE FLT3 is one of the most frequently mutated genes in acute myeloid leukemia. 23846442 2013
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with a normal karyotype. 21242187 2011
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Our results indicate an association of FLT3/ITD with the adverse outcome in AML patients treated with standard induction chemotherapy. 17579862 2007
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Only a few investigations have focused on the prognostic significance of FLT3 alterations in AML among the elderly, yielding conflicting results. 15059064 2004
Entrez Id: 1050
Gene Symbol: CEBPA
CEBPA
1.000 GeneticVariation disease BEFREE Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. 22389883 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE In this study, we compared the FLT3 mutational status between diagnosis and subsequent relapses in 31 patients with AML. 15289019 2004
Entrez Id: 1050
Gene Symbol: CEBPA
CEBPA
1.000 GeneticVariation disease BEFREE Subtyping of acute myeloid leukemia requires an integration of information from the patient's clinical history (such as any prior preleukemic myeloid neoplasm or cytotoxic potentially leukemogenic therapy), the leukemia morphology, cytogenetic findings, and the mutation status of particular genes (NPM1, FLT3, and CEBPA). 23590662 2013
Entrez Id: 1050
Gene Symbol: CEBPA
CEBPA
1.000 GeneticVariation disease BEFREE Altogether, these results identified the co-occurrence of mutations in CSF3R and CEBPA in a well-defined AML subset, which uniformly responds to JAK inhibitors and paves the way to personalized clinical trials for this disease. 27034432 2016
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE The p53 response was critical to the observed changes as the Flt3-ITD had no effect on chemotherapy response in the setting of p53 null AML. 21288478 2011
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE The haematopoietic growth factor receptor Flt3 has been implicated as major cause of transformation in acute myeloid leukaemia. 19438505 2009
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE These results provide pre-clinical and clinical evidence for an effective combinatorial treatment strategy targeting XPO1 and FLT3 in <i>FLT3</i>- mutated acute myeloid leukemias. 29773601 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE FLT3-ITD and FLT3 point mutations were present in 27 (32%) of the AML patients. 17156841 2007
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Abstract Several molecular markers, such as NPM1, FLT3 and CEBPA, have been incorporated into both the World Health Organization and European LeukemiaNet classifications as routine assessments for the diagnosis and evaluation of prognostic significance in acute myeloid leukemia (AML). 23150981 2013
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE FLT3-ITD and its current role in acute myeloid leukaemia. 28470536 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Our data suggest that sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT, and whether sorafenib combined with chemotherapy followed by DLI reveals an optimal efficacy merits further study. 31009704 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE The FLT3 internal tandem duplication (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD) were analyzed by polymerase chain reaction (PCR) in the genomic DNA of Korean patients with AML at diagnosis and during follow-up. 18955790 2008
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE Our results confirm that FLT3 activating mutations also occur in a significant percentage in Chinese AML patients. 15996732 2005
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE The combination of midostaurin or gilteritinib with venetoclax potently and synergistically induces apoptosis in FLT3-ITD AML cell lines and primary patient samples. 31320594 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Thus, FLT3-ITD confers a resistance to the proteasome inhibitors on AML cells by protecting the mTORC1/Mcl-1 pathway through the STAT5/Pim axis, and inhibition of these signaling events remarkably enhances the therapeutic efficacy. 30472492 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE A tandem duplication of exon 11 of FLT3 was harbored by two of 58 (3%) patients with MDS and five of 34 (15%) with overt leukemia, including MDS-derived leukemia, AML/TMDS and therapy-related leukemia. 9305595 1997
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Seventeen patients with FLT3-ITD positive AML were treated with sorafenib in combination with allogeneic HSCT. 26233683 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 GeneticVariation disease BEFREE FLT3 mutation status of 630 children with de novo acute myeloid leukemia (AML) treated on CCG-2941 and -2961 was determined, and ITD-AR was calculated for patients with FLT3/ITD. 16912228 2006
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. 10192423 1999
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
1.000 Biomarker disease BEFREE Thus, TKIs with first-generation inhibitors fail to eradicate early leukemic stem/progenitor cells in FLT3-ITD(+) AML. 21546568 2011